Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2020

01-12-2020 | Mesothelioma | ASO Author Reflections

ASO Author Reflections: Improving Outcomes in Diffuse Malignant Peritoneal Mesothelioma: Challenges and Opportunities

Authors: Joshua C. Leinwand, MD, MSE, Michael D. Kluger, MD, MPH

Published in: Annals of Surgical Oncology | Special Issue 3/2020

Login to get access

Excerpt

Cytoreductive surgery with heated intraperitoneal chemotherapy (CRS/HIPEC) has been transformative in the treatment of peritoneal surface malignancies and is standard of care for diffuse malignant peritoneal mesothelioma (DMPM). In contrast to systemic chemotherapy or resection alone, CRS/HIPEC can address both macroscopic disease surgically as well as microscopic disease with high local concentrations of chemotherapy and also confers the synergistic cytotoxic and pharmacokinetic benefits of hyperthermia. Two large multi-institutional series previously established the safety and efficacy of CRS/HIPEC for DMPM and identified demographic, disease, and treatment factors associated with durable responses in these patients.1,2 Our study sought to examine the outcomes of an intent-to-treat series of DMPM patients from a single institution who underwent two planned CRS/HIPEC operations with serial dwell intraperitoneal chemotherapy in the interval between operations.3 …
Literature
1.
Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237-42.CrossRef
2.
Alexander HR Jr, Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153(6):779-86.CrossRef
3.
4.
Sgarbura O, Gourgou S, Tosi D, Bakrin N, Bouazza N, Delaine S, et al. MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma. Pleura Peritoneum. 2019;4(2):20190010.CrossRef
5.
Sugahara KN, Scodeller P, Braun GB, de Mendoza TH, Yamazaki CM, Kluger MD, et al. A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis. J Control Release. 2015;212:59-69.CrossRef
Metadata
Title
ASO Author Reflections: Improving Outcomes in Diffuse Malignant Peritoneal Mesothelioma: Challenges and Opportunities
Authors
Joshua C. Leinwand, MD, MSE
Michael D. Kluger, MD, MPH
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue Special Issue 3/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08286-z

Other articles of this Special Issue 3/2020

Annals of Surgical Oncology 3/2020 Go to the issue

ASO Author Reflections

ASO Author Reflections: Total Lesion Glycolysis Ratio in Positron Emission Tomography and Computed Tomography Images During Neoadjuvant Chemotherapy: Usefulness and Perspectives as an Evaluation Tool for the Effect of Neoadjuvant Treatment on Esophageal Squamous Cell Carcinoma

ASO Author Reflections

ASO Author Reflections: Influence of Patient Clinical- and Treatment-Level Factors on Religious/Spiritual Preferences During Cancer Care

Correction

Correction to: The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection

ASO Author Reflections

ASO Author Reflections: What is the Most Appropriate Surgical Management for Men with Breast Cancer?

ASO Author Reflections

ASO Author Reflections: Prognostic Value of the Preoperative Tumor Marker Index in Resected Pancreatic Ductal Adenocarcinoma: A Retrospective Single Institutional Study

ASO Author Reflections

ASO Author Reflections: Portal Vein Leiomyosarcoma: How to Perform a Major Hepatectomy with Biliary and Portal Vein Reconstruction Using an Autogenous External Iliac Vein Interposition Graft